Other languages Altimmune, Inc.

Equities

ALT

US02155H2004

Real-time Estimate Cboe BZX Other stock markets 11:13:17 2024-06-10 am EDT			5-day change	1st Jan Change
6.415 ^USD	-0.62%		-13.61%	-42.48%

Jun. 05	Altimmune, Inc. Presents Data at EASL International Liver Congress?? 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis	CI
May. 23	Transcript : Altimmune, Inc. Presents at UBS Obesity Therapeutics Day, May-23-2024 10:00 AM

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Altimmune, Inc. Presents Data at EASL International Liver Congress?? 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis	Jun. 05
Altimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
Altimmune Shares Decline After Guggenheim Downgrade	Apr. 29
Altimmune Shares Slip Wednesday, After Reporting a Wider Q4 Net Loss and Dropping Prospective Treatment for Hepatitis B	Mar. 27
Altimmune, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 27
Drugmakers deepen efforts to tap into booming market for obesity drugs	Feb. 27
Zealand shares surge on liver drug data from Boehringer pact	Feb. 26
Altimmune shares slide after Kerrisdale Capital takes short position	Feb. 13
Weight loss drug windfall attracts pharma companies	Jan. 11
Drugmakers plot way into obesity market with deals and development	Jan. 11
USA: 1000 Dollar monatlich für Anti-Adipositas-Behandlung	Jan. 09
Kosten van een obesitasbehandeling in de VS: 1000 USD per maand	Jan. 07
Negli USA, 1.000 dollari al mese per un trattamento anti-obesità	Jan. 04
En EE.UU., 1.000 dólares al mes por un tratamiento contra la obesidad	Jan. 02
Aux USA, 1000 USD par mois pour un traitement anti-obésité	Jan. 02
Social Buzz: Wallstreetbets Stocks Mostly Up Premarket; Altimmune Poised to Rise, Robinhood Markets to Decline	Dec. 07
Altimmune open to partnerships, deals with drugmakers, says CEO	Dec. 05
Roche enters obesity drugs race with $2.7 bln Carmot deal	Dec. 04
Roche enters obesity drugs race with $2.7 bln Carmot deal	Dec. 04
Wall Street Set to Open Lower Friday as Investors Await Economic Data, Powell Speech	Dec. 01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Altimmune, Inc.

Equities

ALT

US02155H2004

Other languages

Filters